Acelyrin, Inc.(SLRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLRN Acelyrin, Inc.

Market Closed 11-15 16:00:00 EST

4.69

-0.47

-9.11%

盘后4.69

+0.000.00%

18:40 EST

High5.19	Low4.50	Vol753.72K
Open5.19	D1 Closing5.16	Amplitude13.47%
Mkt Cap468.10M	Tradable Cap301.59M	Total Shares99.81M
T/O3.60M	T/O Rate1.17%	Tradable Shares64.30M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"SLRN","market":"US","secType":"STK","nameCN":"Acelyrin, Inc.","latestPrice":4.69,"timestamp":1731704400000,"preClose":5.16,"halted":0,"volume":753715,"hourTrading":{"tag":"盘后","latestPrice":4.69,"preClose":4.69,"latestTime":"18:40 EST","volume":417,"amount":1955.71,"timestamp":1731714031354},"delay":0,"floatShares":64304337,"shares":99808262,"eps":-2.677385,"marketStatus":"Market Closed","change":-0.47,"latestTime":"11-15 16:00:00 EST","open":5.19,"high":5.19,"low":4.495,"amount":3595081.1127250004,"amplitude":0.13469,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.677385,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731920400000},"marketStatusCode":7,"adr":0,"listingDate":1683259200000,"exchange":"NASDAQ","adjPreClose":5.16,"preHourTrading":{"tag":"盘前","latestPrice":5.17,"preClose":5.16,"latestTime":"08:31 EST","volume":6,"amount":31.0699998,"timestamp":1731677460187},"postHourTrading":{"tag":"盘后","latestPrice":4.69,"preClose":4.69,"latestTime":"18:40 EST","volume":417,"amount":1955.71,"timestamp":1731714031354},"volumeRatio":1.47278,"impliedVol":2.3497,"impliedVolPercentile":0.9167},"requestUrl":"/m/hq/s/SLRN","defaultTab":"news","newsList":[{"id":"1199105134","title":"Stock Track | Acelyrin, Inc. (SLRN) Plummets 5.52% Premarket, Reason Unclear","url":"https://stock-news.laohu8.com/highlight/detail?id=1199105134","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199105134?lang=en_us&edition=fundamental","pubTime":"2024-11-15 22:48","pubTimestamp":1731682114,"startTime":"0","endTime":"0","summary":"Shares of Acelyrin, Inc.  plummeted 5.52% in the premarket trading session on Friday. The stock price drop occurred without any apparent catalyst or significant news that could explain the price movement.The only available information was analyst commentary from Morgan Stanley, where analyst Vikram Purohit maintained a Hold rating on SLRN with a price target of $6.00. However, this rating did not provide any clear reasoning for the premarket selloff.Analysts covering the healthcare sector have b","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Stock Track | Acelyrin, Inc. (SLRN) Plummets 5.52% Premarket, Reason Unclear","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["SLRN"],"gpt_icon":0},{"id":"2483651323","title":"Analysts Offer Insights on Healthcare Companies: ACELYRIN, INC. (SLRN), Cabaletta Bio (CABA) and Mersana Therapeutics (MRSN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483651323","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483651323?lang=en_us&edition=fundamental","pubTime":"2024-11-15 18:31","pubTimestamp":1731666669,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ACELYRIN, INC. (SLRN – Research Report), Cabaletta...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acelyrin-inc-slrn-cabaletta-bio-caba-and-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-acelyrin-inc-slrn-cabaletta-bio-caba-and-mersana-therapeutics-mrsn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4139","CABA","INC","BK4563","MRSN","HCSG","SLRN"],"gpt_icon":0},{"id":"2483323662","title":"Vikram Purohit’s Hold Rating on ACELYRIN, INC.: Awaiting Key Data and Trial Progress for Future Stock Movement","url":"https://stock-news.laohu8.com/highlight/detail?id=2483323662","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483323662?lang=en_us&edition=fundamental","pubTime":"2024-11-15 18:30","pubTimestamp":1731666635,"startTime":"0","endTime":"0","summary":"Analyst Vikram Purohit of Morgan Stanley maintained a Hold rating on ACELYRIN, INC. (SLRN – Research Report), retaining the price target of $6.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/vikram-purohits-hold-rating-on-acelyrin-inc-awaiting-key-data-and-trial-progress-for-future-stock-movement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/vikram-purohits-hold-rating-on-acelyrin-inc-awaiting-key-data-and-trial-progress-for-future-stock-movement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLRN","INC","PRGS"],"gpt_icon":0},{"id":"2483849885","title":"Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2483849885","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483849885?lang=en_us&edition=fundamental","pubTime":"2024-11-14 15:17","pubTimestamp":1731568641,"startTime":"0","endTime":"0","summary":"For the complete transcript of the earnings call, please refer to the full earnings call transcript.Acelyrin Inc  has strategically refocused its pipeline to prioritize the development of its lead product candidate, Magua map, for thyroid eye disease .The company has shown positive proof of concept data for Magua map, demonstrating rapid improvements in proptosis and clinical activity scores within three weeks.Acelyrin Inc  has completed a positive end of phase two meeting with the FDA, achieving alignment on important elements of the phase three registrational program.The company has resolved outstanding manufacturing commitments, transforming a significant contractual liability into a net expense of only $7.2 million.If the molar exposure at 160 mg subcutaneous comes slightly lower than 10 mg/kg IV, will that be enough to bring a significant clinical benefit?A: We have done extensive work on ISOBE's potency, showing that 160 mg subcutaneous weekly is equipotent to 10 mg/kg IV of secu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acelyrin-inc-slrn-q3-2024-071721522.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLRN"],"gpt_icon":0},{"id":"2483890209","title":"ACELYRIN, INC. Advances Key Drug Developments","url":"https://stock-news.laohu8.com/highlight/detail?id=2483890209","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483890209?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:38","pubTimestamp":1731559129,"startTime":"0","endTime":"0","summary":"ACELYRIN, INC. ( ($SLRN) ) has released its Q3 earnings. Here is a breakdown of the information ACELYRIN, INC. presented to its investors. ACELYRIN...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/acelyrin-inc-advances-key-drug-developments?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/acelyrin-inc-advances-key-drug-developments?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","SLRN","INC"],"gpt_icon":0},{"id":"2483306897","title":"ACELYRIN Inc reports results for the quarter ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2483306897","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483306897?lang=en_us&edition=fundamental","pubTime":"2024-11-14 12:16","pubTimestamp":1731557804,"startTime":"0","endTime":"0","summary":"* ACELYRIN Inc    reported a quarterly adjusted loss of 49 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -87 cents.  The ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN"],"gpt_icon":0},{"id":"2483895542","title":"ACELYRIN, INC. Receives Buy Rating from Tyler Van Buren Due to Clinical Progress and Strategic Advancements","url":"https://stock-news.laohu8.com/highlight/detail?id=2483895542","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483895542?lang=en_us&edition=fundamental","pubTime":"2024-11-14 10:25","pubTimestamp":1731551122,"startTime":"0","endTime":"0","summary":"ACELYRIN, INC. (SLRN) has received a new Buy rating, initiated by TD Cowen analyst, Tyler Van Buren. Tyler Van Buren has given his Buy rating due t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/acelyrin-inc-receives-buy-rating-from-tyler-van-buren-due-to-clinical-progress-and-strategic-advancements?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/acelyrin-inc-receives-buy-rating-from-tyler-van-buren-due-to-clinical-progress-and-strategic-advancements?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLRN","INC","PRGS","TYL"],"gpt_icon":0},{"id":"2483349861","title":"BRIEF-Acelyrin Inc Files For Mixed Shelf Of Up To $400 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483349861","media":"reuters","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483349861?lang=en_us&edition=fundamental","pubTime":"2024-11-14 07:07","pubTimestamp":1731539262,"startTime":"0","endTime":"0","summary":"BRIEF-Acelyrin Inc Files For Mixed Shelf Of Up To $400 Million - SEC FilingNov 13 (Reuters) - ACELYRIN Inc SLRN.O:ACELYRIN INC FILES FOR MIXED SHELF OF UP TO $400 MILLION - SEC FILINGSource text: [ID:n0001193125-24-257383]Further company coverage: SLRN.O ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK36O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","BK4139"],"gpt_icon":0},{"id":"2483667688","title":"ACELYRIN Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2483667688","media":"THOMSON REUTERS","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483667688?lang=en_us&edition=fundamental","pubTime":"2024-11-14 06:26","pubTimestamp":1731536819,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nFWN3MK36O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLRN"],"gpt_icon":0},{"id":"2483215865","title":"Acelyrin Q3 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2483215865","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483215865?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:59","pubTimestamp":1731535151,"startTime":"0","endTime":"0","summary":"Acelyrin  reported a Q3 net loss late Wednesday of $0.49 per diluted share, narrowing from a loss of $0.87 a year earlier.Analysts polled by Capital IQ expected loss of $0.81.Cash, cash equivalents and short-term marketable securities as of Sept. 30 were $562.4 million, according to the company.Acelyrin said it expects these to fund operations to mid-2027.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","SLRN"],"gpt_icon":0},{"id":"2483850129","title":"Acelyrin Q3 2024 GAAP EPS $(0.49) Beats $(0.75) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2483850129","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483850129?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:01","pubTimestamp":1731531682,"startTime":"0","endTime":"0","summary":"Acelyrin (NASDAQ:SLRN) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.75) by 34.67 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41953659/acelyrin-q3-2024-gaap-eps-0-49-beats-0-75-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Acelyrin Q3 2024 GAAP EPS $(0.49) Beats $(0.75) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN"],"gpt_icon":0},{"id":"2483385010","title":"BRIEF-ACELYRIN Q3 EPS USD -0.49 Vs. IBES Estimate USD -0.8","url":"https://stock-news.laohu8.com/highlight/detail?id=2483385010","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483385010?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:00","pubTimestamp":1731531645,"startTime":"0","endTime":"0","summary":"Nov 13 (Reuters) - ACELYRIN Q3 operating expenses USD 54.747 million. * Q3 income from operations USD -54.747 million vs. IBES estimate USD -81.1 million * Q3 net income USD -48.548 million vs. IBES estimate USD -77.2 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USD","SLRN"],"gpt_icon":0},{"id":"2483850114","title":"ACELYRIN Inc:  Expects Cash, Cash Equivalents & Short-Term Marketable Securities at September 30, 2024 to Fund Operations to Mid-2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2483850114","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483850114?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:00","pubTimestamp":1731531600,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241113:nTUA3Z5V1L:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLRN"],"gpt_icon":0},{"id":"2483850434","title":"Press Release: ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483850434","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483850434?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:00","pubTimestamp":1731531600,"startTime":"0","endTime":"0","summary":"Topline data from Phase 2b/3 trial of izokibep as a treatment for non-infectious non-anterior uveitis expected in December 2024. Positive lonigutamab EOP2 FDA interaction completed and initiation of subcutaneous Phase 3 development program in thyroid eye disease  expected in Q1 2025. Cash, cash equivalents, and short-term marketable securities at September 30, 2024 of $562.4 million projected to provide cash runway to mid-2027. \"We are executing on our refocused pipeline strategy and are excited by the near-term catalysts ahead for ACELYRIN, particularly as we advance subcutaneous lonigutamab into Phase 3 development as the next generation IGF-1R inhibitor for thyroid eye disease. We recently concluded a positive end of phase 2 interaction with the FDA, established a world-class scientific and patient advisory board, and remain on track to initiate our Phase 3 development program in TED next quarter,\" said Mina Kim, Chief Executive Officer of ACELYRIN. \"We are also looking forward to a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAS","INC","SLRN","BK4139"],"gpt_icon":0},{"id":"2483488077","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2483488077","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483488077?lang=en_us&edition=fundamental","pubTime":"2024-11-13 19:00","pubTimestamp":1731495600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MCRB","DFLI","KRMD","ENLT","MIST","AMAT","LVLU","HBM","JD","CINT","EXAI","DTI","GLOB","INVZ","ASND","BN","DGII","LQDA","HI","SONO","AFCG","GAMB","BRFS","DNMR","SHCO","INKT","ADAP","BRAG","DMAC","KORE","CPRT","UGP","ICAD","SLE","BLRX","CIG","HAYN","MURA","KMDA","BZH","INO","SLRN","GOEV","BOXL","CELC","IVVD","BEEM","CREX","EC"],"gpt_icon":1},{"id":"2482876712","title":"ACELYRIN Inc  expected to post a loss of 80 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482876712","media":"reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482876712?lang=en_us&edition=fundamental","pubTime":"2024-11-12 11:52","pubTimestamp":1731383546,"startTime":"0","endTime":"0","summary":"ACELYRIN Inc  expected to post a loss of80cents a share - Earnings Preview ACELYRIN Inc SLRN.OQ SLRN.O is expected to show no change in quarterly revenue when it reports  results on November 13 for th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241112:nL8N3MJ0B6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN"],"gpt_icon":0},{"id":"2481596959","title":"ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481596959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481596959?lang=en_us&edition=fundamental","pubTime":"2024-11-07 05:00","pubTimestamp":1730926800,"startTime":"0","endTime":"0","summary":"LOS ANGELES, Nov.  06, 2024  (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/06/2975992/0/en/ACELYRIN-INC-to-Report-Third-Quarter-2024-Financial-Results-and-Corporate-Update-on-November-13-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","BK4139","INC"],"gpt_icon":0},{"id":"2475965400","title":"ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2475965400","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475965400?lang=en_us&edition=fundamental","pubTime":"2024-10-16 19:00","pubTimestamp":1729076400,"startTime":"0","endTime":"0","summary":"Experts and advocates to provide important strategic input and clinical expertise as ACELYRIN completes its Phase 2 trial of lonigutamab in TED and prepares to initiate Phase 3 program in rst quarter ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/10/16/2963916/0/en/ACELYRIN-INC-Forms-Scientific-and-Patient-Advisory-Board-Featuring-Leading-Voices-in-Thyroid-Eye-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLRN","BK4139","INC"],"gpt_icon":0},{"id":"2475521509","title":"ACELYRIN Inc : Wells Fargo Raises Target Price to $15  From $13","url":"https://stock-news.laohu8.com/highlight/detail?id=2475521509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475521509?lang=en_us&edition=fundamental","pubTime":"2024-10-16 18:16","pubTimestamp":1729073809,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241016:nFWN3LS0P0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SLRN","BK4139"],"gpt_icon":0},{"id":"2470582172","title":"ACELYRIN, INC. (SLRN) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2470582172","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2470582172?lang=en_us&edition=fundamental","pubTime":"2024-09-25 19:27","pubTimestamp":1727263661,"startTime":"0","endTime":"0","summary":"In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on ACELYRIN, INC. (SLRN – Research Report), with a price targ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/acelyrin-inc-slrn-receives-a-buy-from-piper-sandler-4?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/acelyrin-inc-slrn-receives-a-buy-from-piper-sandler-4?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLRN","INC","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.acelyrin.com","stockEarnings":[{"period":"1week","weight":-0.1328},{"period":"1month","weight":-0.0979},{"period":"3month","weight":0.2494},{"period":"6month","weight":0.1754},{"period":"1year","weight":-0.4361},{"period":"ytd","weight":-0.3083}],"compareEarnings":[{"period":"1week","weight":-0.0038},{"period":"1month","weight":0.0234},{"period":"3month","weight":0.0704},{"period":"6month","weight":0.1207},{"period":"1year","weight":0.3195},{"period":"ytd","weight":0.2483}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody against insulin-like growth factor 1 receptor, which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease; and SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. The company was incorporated in 2020 and is headquartered in Agoura Hills, California.","exchange":"NASDAQ","name":"Acelyrin, Inc.","nameEN":"Acelyrin, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Acelyrin, Inc.(SLRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Acelyrin, Inc.(SLRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Acelyrin, Inc.,SLRN,Acelyrin, Inc.股票,Acelyrin, Inc.股票老虎,Acelyrin, Inc.股票老虎国际,Acelyrin, Inc.行情,Acelyrin, Inc.股票行情,Acelyrin, Inc.股价,Acelyrin, Inc.股市,Acelyrin, Inc.股票价格,Acelyrin, Inc.股票交易,Acelyrin, Inc.股票购买,Acelyrin, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Acelyrin, Inc.(SLRN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Acelyrin, Inc.(SLRN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction